Simmons Bank Has $3.74 Million Position in Pfizer Inc. $PFE

Simmons Bank reduced its stake in Pfizer Inc. (NYSE:PFE) by 1.4% during the second quarter, HoldingsChannel reports. The firm owned 154,393 shares of the biopharmaceutical company’s stock after selling 2,234 shares during the quarter. Simmons Bank’s holdings in Pfizer were worth $3,742,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer in the 1st quarter valued at approximately $27,000. Curio Wealth LLC boosted its position in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares during the period. Bayforest Capital Ltd acquired a new stake in Pfizer during the 1st quarter worth approximately $28,000. Harbor Asset Planning Inc. acquired a new stake in Pfizer during the 2nd quarter worth approximately $29,000. Finally, WPG Advisers LLC acquired a new stake in Pfizer during the 1st quarter worth approximately $35,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently commented on PFE shares. Bank of America lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup lifted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $28.24.

Pfizer Stock Down 1.4%

Pfizer stock opened at $24.32 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $28.00. The firm has a 50 day moving average price of $24.75 and a two-hundred day moving average price of $24.33. The firm has a market cap of $138.24 billion, a price-to-earnings ratio of 12.93, a PEG ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. Pfizer’s payout ratio is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.